Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast  2023-2033

Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Report Format: PDF+Excel | Report ID: SR112023A7121
Buy Now

The focal segmental glomerulosclerosis market has been comprehensively analyzed in IMARC's new report titled "Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033". Focal segmental glomerulosclerosis (FSGS) refers to a condition in which scar tissue forms on the glomeruli, the tiny part of the kidney responsible for removing waste from the blood. This results in damage to the kidney's filtration function and an abnormal loss of protein in the urine. The most common symptoms of the ailment include frothy urine, excess water retention, pitting edema, susceptibility to infection, fatty casts in the urine, etc. Individuals suffering from FSGS may also experience weight gain due to excess fluid building up in the body, high-fat levels in the blood, a poor appetite, fatigue, etc. The diagnosis typically involves a combination of laboratory investigations and imaging studies. A urine test helps in identifying the presence of proteinuria, while a blood test is performed to check for signs of kidney damage, such as elevated creatinine levels. Various imaging studies, including an ultrasound or CT scan, are utilized to visualize the kidneys and check for any abnormalities. Additionally, a renal biopsy, in which a small portion of the kidney is extracted using a special needle and examined under a microscope, is required to confirm the presence of FSGS among patients.

The rising prevalence of several associated risk factors, such as kidney infections, exposure to toxins, genetic mutations, underlying medical conditions like HIV and sickle cell disease, etc., is primarily driving the focal segmental glomerulosclerosis market. In addition to this, the widespread adoption of certain medications, including bisphosphonates, anabolic steroids, anthracyclines, calcineurin inhibitors, etc., that damage renal podocytes is also propelling the market growth. Furthermore, the inflating utilization of corticosteroids in the treatment of FSGS, which prevent the immune system from attacking the glomeruli and affecting renal function, is acting as another significant growth-inducing factor. Apart from this, the escalating application of plasmapheresis to reduce proteinuria and improve kidney function in patients is further creating a positive outlook for the market. Moreover, numerous key players are making extensive investments in R&D activities to launch innovative diagnostic techniques, such as next-generation sequencing technology, that provide higher specificity and sensitivity than conventional methods. This, in turn, is also bolstering the market growth. Additionally, the emerging popularity of anti-hypertensive therapy for treating the ailment since it can reduce the risk of further kidney damage and delay the need for more aggressive treatments, such as dialysis or kidney transplant, is expected to drive the focal segmental glomerulosclerosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the focal segmental glomerulosclerosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for focal segmental glomerulosclerosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the focal segmental glomerulosclerosis market in any manner.

Time Period of the Study

  • Base Year: 2022
  • Historical Period: 2017-2022
  • Market Forecast: 2023-2033
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the focal segmental glomerulosclerosis market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the focal segmental glomerulosclerosis market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs
     

This report also provides a detailed analysis of the current focal segmental glomerulosclerosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance   
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Regulatory Status  

Key Questions Answered in this Report

Market Insights

  • How has the focal segmental glomerulosclerosis market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
  • What was the country-wise size of the focal segmental glomerulosclerosis market across the seven major markets in 2022 and what will it look like in 2033?
  • What is the growth rate of the focal segmental glomerulosclerosis market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2017-2033) of focal segmental glomerulosclerosis across the seven major markets?
  • What is the number of prevalent cases (2017-2033) of focal segmental glomerulosclerosis by age across the seven major markets?
  • What is the number of prevalent cases (2017-2033) of focal segmental glomerulosclerosis by gender across the seven major markets?
  • How many patients are diagnosed (2017-2033) with focal segmental glomerulosclerosis across the seven major markets?
  • What is the size of the focal segmental glomerulosclerosis patient pool (2017-2022) across the seven major markets?
  • What would be the forecasted patient pool (2023-2033) across the seven major markets?
  • What are the key factors driving the epidemiological trend of focal segmental glomerulosclerosis?
  • What will be the growth rate of patients across the seven major markets?
     

Focal Segmental Glomerulosclerosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for focal segmental glomerulosclerosis drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the focal segmental glomerulosclerosis market?
  • What are the key regulatory events related to the focal segmental glomerulosclerosis market?
  • What is the structure of clinical trial landscape by status related to the focal segmental glomerulosclerosis market?
  • What is the structure of clinical trial landscape by phase related to the focal segmental glomerulosclerosis market?
  • What is the structure of clinical trial landscape by route of administration related to the focal segmental glomerulosclerosis market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Focal Segmental Glomerulosclerosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast  2023-2033
Select License Type



Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More